Drugs / DFN-15
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03282838 | Jun → Aug 2017 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT03554772 | Jun → Aug 2018 | — | Dr. Reddy's Laboratories Limited | Completed | Met primary |
| Phase 2 | NCT03472378 | May 2018 → Apr 2019 | allesthesia, migraine with aura, migraine without aura | Hartford Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02472418 | Jun → Dec 2015 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03006276 | Dec 2016 → Nov 2017 | migraine disorder | BioDelivery Sciences International | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFN-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03006276 ↗ |
| Known as | celecoxib | “The analgesic efficacy and safety of DFN-15, a new oral liquid formulation of celecoxib with more rapid absorption than the capsule, were evaluated in the treatment of acute...” PMID 34252915 ↗ Jan 20222“to determine whether oral administration of DFN-15 (solution of a COX2 inhibitor, Celecoxib) terminates migraine attacks” NCT03472378 ↗ “a new oral liquid formulation of celecoxib, DFN-15, in adults with migraine” PMID 29158678 ↗ Nov 2017 |
| Action | Inhibit | “solution of a COX2 inhibitor” NCT03472378 ↗ |
| Route | Oral | “oral liquid formulation” PMID 29158678 ↗ Nov 2017 |